Savara (NASDAQ:SVRA) Trading Down 3.2% – Should You Sell?

Savara Inc (NASDAQ:SVRA) was down 3.2% on Friday . The company traded as low as $3.34 and last traded at $3.36. Approximately 61,820 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 1,250,333 shares. The stock had previously closed at $3.47.

Analysts Set New Price Targets

A number of analysts recently issued reports on SVRA shares. Evercore ISI reissued an “in-line” rating and set a $5.00 price objective (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. HC Wainwright reduced their price target on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Finally, JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Savara Price Performance

The stock has a 50 day moving average of $3.66 and a two-hundred day moving average of $4.08. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The firm has a market capitalization of $576.64 million, a P/E ratio of -7.81 and a beta of 1.02.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). Sell-side analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Savara news, Director Joseph S. Mccracken purchased 20,000 shares of the stock in a transaction dated Tuesday, November 19th. The shares were bought at an average cost of $2.95 per share, with a total value of $59,000.00. Following the completion of the transaction, the director now owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.13% of the company’s stock.

Institutional Trading of Savara

Several hedge funds have recently added to or reduced their stakes in SVRA. Vanguard Group Inc. lifted its holdings in shares of Savara by 2.5% during the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after buying an additional 148,673 shares during the last quarter. CANADA LIFE ASSURANCE Co bought a new position in Savara during the first quarter worth $35,000. Price T Rowe Associates Inc. MD increased its position in Savara by 15.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after acquiring an additional 4,625 shares during the period. California State Teachers Retirement System raised its stake in Savara by 411.0% during the 1st quarter. California State Teachers Retirement System now owns 75,986 shares of the company’s stock valued at $378,000 after purchasing an additional 61,117 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Savara by 12.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 288,325 shares of the company’s stock valued at $1,162,000 after purchasing an additional 32,142 shares during the period. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.